Table 5. . Studies showing the reduced risk of hepatocellular carcinoma, with aspirin use.

Study (year)	Design	Population	Number of patients using aspirin	Key finding aspirin vs nonuse
Sahasrabuddhe et al. (2012)	Prospective cohort study	n = 300,504 HCC patients aged 50–71 years National Institute of Health AARP Diet and Health Study	219,291	HCC development: RR: 0.59; 95% CI: 0.45–0.77 Death due to chronic liver disease: RR: 0.55; 95% CI: 0.45–0.67
Petrick et al. (2015)	Meta-analysis	n = 679 Data from 10 US-based cohort studies in a total of 1,084,133 individuals	315	HCC development: HR: 0.68; 95% CI: 0.57–0.81
Li et al. (2016)	Retrospective matched-pair analysis	n = 120 Patients with HCC treated with TACE and aspirin	60	Mortality risk: HR: 0.498; 95% CI: 0.28–0.888

AARP: American Association of Retired Persons; HCC: Hepatocellular carcinoma; HR: Hazard ratio; RR: Relative risk; TACE: Trans arterial chemo embolization.